GlaxoSmithKline (LON:GSK) Given a GBX 1600 Price Target at UBS

Adjust Comment Print

The institutional investor held 29,700 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $1.05M, down from 41,700 at the end of the previous reported quarter. The stock decreased 0.26% or $0.24 during the last trading session, reaching $92.78. About 2.65 million shares traded or 48.54% up from the average. GSK underperformed the S&P500 by 21.62%. P-R Herzig & Co sold 11,700 shares as the company's stock rose 9.28% while stock markets declined. After $0.72 EPS report last quarter, Wall Street now forecasts -1.39 % negative EPS growth of GlaxoSmithKline plc. Taconic Capital Advisors Lp who had been investing in Genworth Finl Inc for a number of months, seems to be bullish on the $1.36B market cap company. Hmi Capital Llc owns 1.88 million shares or 12.42% of their U.S. portfolio. (NYSE:BRO) has risen 18.96% since April 15, 2017 and is uptrending. It has underperformed by 11.55% the S&P500. Jefferies Group set a GBX 1,600 ($22.61) target price on GlaxoSmithKline and gave the company a "buy" rating in a research note on Friday. Therefore 86% are positive. F&M Bank had 61 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has "Neutral" rating given on Friday, April 29 by Bank of America. The company was upgraded on Wednesday, January 27 by Bryan Garnier & Cie. The stock has "Buy" rating by UBS on Monday, November 27. As per Monday, February 26, the company rating was maintained by Keefe Bruyette & Woods. As per Tuesday, March 6, the company rating was downgraded by CLSA. RBC Capital Markets maintained Owens-Illinois, Inc. The firm earned "Buy" rating on Monday, October 31 by HSBC. The rating was maintained by Roth Capital with "Buy" on Thursday, March 22.

Investors sentiment decreased to 1.11 in 2017 Q4. It's down -0.98, from 2 in 2017Q3. It fall, as 18 investors sold BRO shares while 91 reduced holdings. 28 funds opened positions while 10 raised stakes. 306.90 million shares or 2.61% less from 315.12 million shares in 2017Q3 were reported. Manufacturers Life Insur Com The accumulated 447,348 shares. (NYSE:AYI) stake by 8,188 shares to 3,805 valued at $670,000 in 2017Q4. (NYSE:BRO). Royal Natl Bank Of Canada has 0.01% invested in Brown & Brown, Inc. Profund Advsrs Ltd Liability holds 0.05% or 95,396 shares. Geode Cap Management Ltd Liability Corp reported 3.99 million shares. (NYSE:HBI). Greenleaf Trust stated it has 436 shares.

LPL Financial Holdings Inc., together with its subsidiaries, provides an integrated platform of brokerage and investment advisory services to independent financial advisors in the United States. (NYSE:GNW). 15,000 are owned by Fort Washington Investment Advsrs Oh. Switzerland-based Credit Suisse Ag has invested 0.01% in Brown & Brown, Inc. Barclays Capital upgraded GlaxoSmithKline plc (NYSE:GSK) on Tuesday, January 16 to "Buy" rating. Analysts predict $0.71 earnings per share, which is $0.09 up or 14.52 % from 2017's $0.62 earnings per share. In case of $0.71 earnings per share GSK's profit could be $1.69B.

More news: UFC Glendale: Dustin Poirier demands title shot after stopping Justin Gaethje cold
More news: Putin sits back as U.S. , allies strike Syria
More news: F1: Sebastian Vettel seals pole for Chinese Grand Prix

John G Ullman & Associates Inc, which manages about $1.08 billion and $501.27M US Long portfolio, upped its stake in Vanguard S&P 500 Etf (VOO) by 1,352 shares to 2,557 shares, valued at $627,000 in 2017Q4, according to the filing. It also reduced Dollar Tree Inc (NASDAQ:DLTR) stake by 76,550 shares and now owns 228,070 shares.

One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and nine have assigned a buy rating to the company. Therefore 48% are positive. Oracle had 114 analyst reports since July 30, 2015 according to SRatingsIntel. The firm earned "Neutral" rating on Wednesday, April 26 by JP Morgan. On Wednesday, April 4 the rating was upgraded by BNP Paribas to "Buy". Morgan Stanley downgraded the stock to "Underweight" rating in Friday, September 8 report.

Analysts await GlaxoSmithKline plc (NYSE:GSK) to report earnings on April, 25.